Study Summary
The purpose of this study is to deliver dual-targeting CAR-T cell therapy (CART 2219.1) as a salvage treatment to patients with relapsed/refractory B-lineage leukaemia in place of stem cell transplant or irradiation.
Want to learn more about this trial?
Request More InfoInterventions
Phase IBIOLOGICAL
* Dose level 0: CAR+CD3+ 0.4 x 10e6/kg (de-escalation dose)
* Dose level 1: CAR+CD3+ 1 x 10e6/kg (starting dose)
* Dose level 2: CAR+CD3+ 2.5 x 10e6/kg.
Dose-escalations for adults and paediatrics will be performed in 2 independent strata for determination of RP2D.
Phase IIBIOLOGICAL
RP2D will be determined in Phase I
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| KK Women's and Children's hospital | Singapore | Singapore |